Fresh off Kite and BeiGene deals, Shoreline ups the ante with a hefty crossover. But the biotech insists it's in no rush
Though it may seem like Shoreline Biosciences is rapidly gaining momentum with a flurry of deals — and, now, a new funding round — Kleanthis Xanthopoulos doesn’t feel he’s in a rush.
The biotech’s chief executive put the bow on a $140 million Series B on Tuesday, as Shoreline continues a streak of wheeling and dealing that’s seen it partner with Gilead’s Kite and BeiGene these last few months. And despite the new raise technically being a crossover round with Ally Bridge Group leading the way, Xanthopoulos is taking his time in prepping a public offering.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.